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Background: The open approach represents the gold standard for postchemotherapy retroperitoneal lymph node
dissection (O-PCLND) in patients with residual testicular cancer. We analyzed laparoscopic postchemotherapy
retroperitoneal lymph node dissection (L-PCLND) and O-PCLND at our institution.
Methods: Patients underwent either L-PCLND (n = 43) or O-PCLND (n = 24). Categorical and continuous variables
were compared using the Fisher exact test and Mann–Whitney U test respectively. Overall survival was evaluated
with the log-rank test.
Results: Primary histology was embryonal cell carcinomas (18 patients), pure seminoma (2 cases) and mixed NSGCTs (47
patients). According to the IGCCCG patients were categorized into “good”, “intermediate” and “poor prognosis” disease in
55.2%, 14.9% and 20.8%, respectively. Median operative time for L-PCLND was 212 min and 232 min for O-PCLND
(p=0.256). Median postoperative duration of drainage and hospital stay was shorter after L-PCLND (0.0 vs. 3.5 days;
p< 0.001 and 6.0 vs. 11.5 days; p=0.002). Intraoperative complications occurred in 21.7% (L-PCLND) and 38.0% (O-PCLND)
of cases with 19.5% and 28.5% of Clavien Grade III complications for L-PCLND and O-PCLND, respectively (p=0.224).
Significant blood loss (>500 ml) was almost equally distributed (8.6% vs. 14.2%: p=0.076). No significant differences were
observed for injuries of major vessels and postoperative complications (p= 0.758; p= 0.370). Tumor recurrence occurred in
8.6% following L-PCLND and in 14.2% following O-PCLND with a mean disease-free survival of 76.6 and 89.2 months,
respectively. Overall survival was 83.3 and 95.0 months for L-PCNLD and O-PCLND, respectively (p=0.447).
Conclusions: L-PCLND represents a safe surgical option for well selected patients at an experienced center.
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MetastasisBackground
PCLND plays an important role in the management of
patients with advanced seminomatous and NSGCT
[1-5]. The technical advances in radiographic staging and
the increased use of tumor markers have improved the
correct identification of candidates for PCLND [6]. How-
ever, even with the introduction of FDG-PET for staging* Correspondence: stefan.hinz@charite.de
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reproduction in any medium, provided the orof postchemotherapy seminoma patients we cannot reli-
ably rule out viable disease in residual GCT [7]. Postche-
motherapy residual masses in patients suffering from non-
seminoma should be resected according to large retro-
spective series and the most recent urological guidelines
[6,8]. Traditionally, this resection is performed by an open
surgical approach (O-PCLND) - a technically demanding
procedure which should be limited to experienced tertiary
referral centers [9,10]. The extension of the dissection var-
ies from a radical bilateral approach to a more limited
lumpectomy. Full bilateral resection is the standard of carehis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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patients by Heidenreich et al. revealed that in well-defined
masses a modified template resection does not worsen
oncological outcome, but considerably decreases treat-
ment morbidity [11].
O-PCLND is associated with a significant intra- and
postoperative morbidity resulting in prolonged hospital
stays frequently. Subramanian and colleagues analyzed
96 O-PCLND patients and reported intraoperative,
postoperative and late complications in 12%, 32% and
7% of cases, respectively of which 8% were classified as
Clavien Grade III/IV complications [12,13].
The complication rate of primary laparoscopic
retroperitoneal lymph node dissection in stage I GCTs
varies widely in the literature with incidences of 2.2-20%,
the majority of with are vascular injuries [14]. For L-
PCLND complication rates of up to 43.8% have been
reported, necessitating a high level of laparoscopic training
for its prevention [14,15]. At the time of L-PCNLD imple-
mentation, smaller series with high conversion rates to
open surgery have been reported [16]. However, more re-
cent data restricted to small tumors proved that L-PCLND
is feasible and has morbidity rates comparable to O-
PCLND [17,18]. So far no study has directly compared intra
and postoperative data of L-PCLND patients to a contem-
porary O-PCLND cohort. Consequently, L-PCLND has not
been recommended as a standard surgical approach for
patients with residual masses following chemotherapy for
advanced testicular cancer [1,4,6].Results
Preoperative patient’ characteristics
A total of 18 patients showed evidence of seminomatous
fractions in the primary histology report at the time of
orchiectomy (L-PCLND: n= 12; 26.0% and for O-PCLND:
n= 6; 28.5%). Two patients of the L-PCLND group had
pure seminoma. The most common primary histology was
mixed NSGCT (n=47) with a predominance of ECC in
35 patients (52.2%). There were no statically significant
differences with respect to histological subtypes between
the two groups except for pure ECC (p= 0.030). Baseline
patient characteristics including primary histology,
IGCCG prognostic risk scores and number of chemother-
apy cycles are displayed in Table 1. Good prognosis
patients were more likely to undergo L-PCLND than O-
PCLND (63.0% vs. 38.0%; p = 0.021). Ten patients demon-
strated S1 tumor marker levels post-chemotherapy. How-
ever, all of these patients had a massive decline in marker
levels from S3/S2 to S1 and/or a radiological response
with significantly decreased tumor extend. A total of 35
patients (52.2%) had clinical stage IIa-IIc disease, while the
remaining patients (47.8%) had clinical stage IIIa-IIIc dis-
ease. There were no statistically significant differences ofthe two surgical cohorts with respect to tumor stage
(p= 0.586; Table 2).
Residual tumor characteristics
A detailed analysis of the residual tumor localisation and
residual tumor histology is demonstrated in Table 3.
Median residual tumors were significantly smaller in
L-PCLND compared to O-PCLND (2.2 cm vs. 6.7 cm;
p = 0.002) (Table 3).
Operative characteristics
L-PCLND was performed in 46 patients, whereas 21
patients underwent O-PCLND. Median age at the time of
surgery was 32.0 years (range 26.5–37.5) and 28.0 years
(range 22.0–34.0), mean BMI 24.0 kg/m2 and 22.6 kg/m2
for O-PCLND and L-PCLND, respectively (p= 0.521).
There were no statistically significant differences with re-
spect to these two variables (p= 0.789). Similarly, the oper-
ating time was equivalent (212 vs. 232 min; p = 0.256).
Median duration of postoperative drainage (0 vs. 3.5 days;
p< 0.001) and median hospital stay (6.0 vs. 11.5 days;
p = 0.002) were significantly shorter after L-PCLND.
The extend of retroperitoneal lymph node dissec-
tion differed significantly: Radical bilateral lymph
node resection was performed in 26.0% and 61.9%, a
modified unilateral approach in 69.5% and 23.8% and
a simple lumpectomy in 4.3% and 0% of patients
undergoing O-PCNLD and L-PCLND, respectively
(p = 0.002).
Intraoperative complications occurred in 10 of the
L-PCLND and in 8 of the O-PCLND patients (21.7% vs.
38.0%). According to Clavien, the incidence of Grade III
intraoperative complications was 19.6% for L-PCLND and
28.5% for O-PCLND (p=0.244). Due to intraoperative
complications, 6.5% of the L-PCLND had to be converted
O-PCLND. A significant blood loss >500 ml occurred in
8.6% and 14.2% of cases during L- PCLND O-PCLND,
respectively (p=0.076). A simultaneous nephrectomy was
necessary in 3 of the O-PCLND patients (14.3%) while
none of the patients received a nephrectomy in the
L-PCLND cohort (p=0.028). Vascular injuries occurred in
26.0% and 19.0% of procedures during L-PCLND and
O-PCLND, respectively (p=0.758). Postoperative complica-
tions were observed in 4 L-PCLND and 3 O-PCLND
patients (8.6% vs. 14.2%; p=0.370; Table 2). One O-PCLND
patient underwent a relaparotomy due to a suspected small
bowel obstruction three days postoperatively. Table 4
depicts a detailed analysis of intraoperative Clavien III com-
plications for both groups. Significant injuries of major ves-
sels (V. cava or aorta) were more frequent in the L-PCLND
cohort 26.0 vs. 19.0%, p=0.758). In univariate analysis,
residual tumor size (RR 1.24; CI 1.05-1.47; p= 0.010) and
the number of chemotherapy cycles (RR 2.90; CI 1.50-5.63;
p=0.002) were the two only significant predictors of grade
Table 1 Preoperative patients’ characteristics
Variable L-PCLND O-PCLND p
ValueN= 46 N=21
histology of orchiectomy; n (%) *2
seminoma*2 12 (26.0) 6 (28.5) 1.000 *1
pure seminoma 2 (4.3) 0 (0) 1.000 *1
teratoma*2 9 (19.5) 4 (19.0) 1.000 *1
embryonal cell carcinoma 25 (54.3) 10 (47.6) 0.558 *1
pure embryonal cell carcinoma 16 (34.7) 2 (9.5) 0.030 *1
chorioncarcinoma*2 2 (4.3) 4 (19.0) 0.077 *1
yolk sack*2 7 (15.2) 8 (38.0) 0.055 *1
IGCCCG risk score before chemotherapy; n (%)
good 29 (63.0) 8 (38.1) 0.021 *1
intermediate 9 (19.6) 1 (4.8)
poor 6 (13.0) 8 (38.1) 0.072 *1
missing 2 (4.3) 4 (19.0)
Tumor markers before chemotherapy; n (%)
Not elevated 5 (10.9) 1 (4.8) 0.065 *1
S1 30 (65.2) 8 (38.1)
S2 5 (10.9) 5 (23.8)
S3 6 (13.0) 7 (33.3)
Tumor markers after chemotherapy; n (%)
Not elevated 38 (82.6) 15 (71.4) 0.545 *1
S1 6 (13.0) 4 (19.0)
missing 2 (4.3) 2 (9.5)
Cycles of chemotherapy preop; median (range) 3 (3-8) 4 (3-7) 0.005 *3
Salvage chemotherapy; n (%) 0 (0) 2 (9.5) 0.095 *1
Abbreviations
L-PCLND – laparoscopic postchemotherapy retroperitoneal lymph node dissection; O-PCLND – open postchemotherapy retroperitoneal lymph node dissection;
IGCCCG – international germ cell cancer collaboration group; preop – preoperatively (before L-PCLND or O-PCLND); *1 – fishers exact test; *2 proportion of
histologic subtype among others, multiple proportions possible; *3 – Man Whitney U test.
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proach on the other hand was not associated with intra or
postoperative complication rate (p=0.243).Outcome characteristics
Postinterventionally, a total of 33 L-PCLND patients and
12 O-PCLND patients underwent surveillance with
regular follow-up visits; additional chemotherapy cycles
were applied to 6.5% and 28.5% of patients following
L-PCLND and O-PCLND, respectively (p = 0.020). One
patient of the L-PCLND cohort required thoracotomy
due to an intrathoracic residual tumor. Three patients
were lost to follow-up and detailed follow-up data was
not available for nine cases. At a median follow-up of
30.1 (L-PCLND) and 54.5 months (O-PCLND), a total
of 7 patients experienced disease recurrence, 8.6% (n = 4)
following L-PCLND and 14.2% (n = 3) following O-PCLND. Detailed information on patient characteristics
of these seven patients are displayed in Table 5.
The mean estimated recurrence-free survival was
76.6 months (CI: 68.4-84.8) for L-PCND and 89.2 months
(CI: 71.6-106.9) for O-PCLND patients (p= 0.521) with no
statistically significant differences between the two
cohorts. Similarly, no significant differences in the mean
estimated OS were detected (L-PCLND: 83.3 months,
CI: 79.6 - 87.3; O-PCLND: 95.0 months, CI: 80.5–109.6;
p = 0.447) (Table 6 and Figure 1). In univariate cox regres-
sion analysis no predictor of recurrence-free and/or OS
was identified. This analysis included surgical technique,
IGCCCG risk score, clinical stage and residual tumor
diameter (data not shown).
Discussion
In our study comparing O-PCLND and L-PCLND long-
term oncological outcome was excellent for both
Table 2 Operative characteristics at PCLND
Variable L-PCLND O-PCLND p Value
N=46 N=21
Clinical stage Lugano; n (%)
CS IIa 6 (13.0) 1 (4.8) 0.586 *1
CS IIb 14 (30.4) 5 (23.8)
CS IIc 6 (13.0) 3 (14.3)
CS IIIa 7 (15.2) 2 (9.5)
CS IIIb 5 (10.9) 2 (9.5)
CS IIIc 8 (17.4) 8 (38.1)
Resected template; n (%)
radical bilateral 12 (26.0) 13 (61.9) 0.002 *1
modified template resection*3 32 (69.5) 5 (23.8)
lumpectomy 2 (4.3) 0 (0)
Median age; yrs (IQR) 32.0 (26.5 – 37.5) 28.0 (22.0 – 34.0) 0.521 *2
Median BMI; kg/m2 (IQR) 24.0 (21.8 – 26.2) 22.6 (19.3 – 25.8) 0.789 *2
Median operative time; min (IQR) 212.0 (145 – 298) 232.5 (181 – 424) 0.256 *2
Insertion of wound drainage tube; n (%) 12 (26.0) 15 (71.4) <0.001 *1
Median duration of drainage tube; days (IQR) 0.0 (0.0 – 1.0) 3.5 (2.0 – 6.5) <0.001 *2
Median duration of hospital stay; days (IQR) 6.0 (5.0 – 7.5) 11.5 (7.0 – 16.5) 0.002 *2
Intraoperative complications; n (%)
none 36 (78.3) 13 (61.9) 0.244 *1
Clavien I 0 (0) 1 (4.7)
Clavien II 1 (2.2) 1 (4.7)
Clavien III 9 (19.6) 6 (28.5)
Intraoperative conversion rate; n (%) 3 (6.5) 0 (0) n.a.
Blood loss categories; n (%)
n.s.< 100 ml 41 (89.1) 15 (71.4) 0.076 *1
100-500 ml without transfusion 1 (2.1) 3 (14.2)
>500 ml or transfusion 4 (8.6) 3 (14.2)
Intraoperative kidney resection; n (%) 0 (0) 3 (14.3) 0.028 *1
Major vascular injuries; n (%) 12 (26.0) 4 (19.0) 0.758 *1
Postoperative complications; n (%)*4 0.431 *1
none 41 (89.1) 18 (85.7)
Clavien I 4 (8.7) 2 (9.5)
Clavien III 0 (0) 1 (4.8)
Abbreviations
L-PCLND – laparoscopic postchemotherapy retroperitoneal lymph node dissection; O-PCLND – open postchemotherapy retroperitoneal lymph node dissection;
CS – clinical stage; yrs – years; IQR – interquartile range; n.a. – not applicable; *1 – fishers exact test; *2 – Mann–Whitney U test; *3 – modified template
resection = nerve sparing technique or unilateral resection; *4 – information for one patient in the L-PCLND group was missing.
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differences between the two cohorts with respect to
intraoperative complications. L-PCLND patients were
less likely to receive surgical drains. There has been a
trend towards a shorter operative time and hospital stay
following L-PCLND. To overcome possible confounding
factors, like the relatively small number of patients, the
retrospective nature of the study and the differences inmedian residual tumor diameter of the two cohorts, we
performed a subgroup analysis of patients with tumor
diameters of ≤7 cm. This analysis confirmed the less fre-
quent placement of surgical drains, the shorter duration
of drainage and hospital stay. However, despite these
efforts, the O-PCLND group was relatively small and the
majority of patients had residual tumors larger than
3 cm. Therefore, a sample selection bias might have
Table 3 Residual tumor characteristics
Variable L-PCLND O-PCLND p-
valueN=46 N=21
Residual tumor localisation; n (%)
paraaortal 34 (73.9) 13 (61.9) 0.392 *1
paracaval 6 (13.0) 4 (19.0) 0.713 *1
interaortocaval 10 (21.7) 5 (23.8) 1.000 *1
iliacal 5 (10.8) 1 (4.7) 0.654 *1
Residual tumor histology; n (%) *3
fibrous scar 28 (60.9) 10 (47.6) 0.426 *1
mature teratoma 12 (26.1) 5 (23.8) 1.000 *1
vital carcinoma 10 (21.7) 5 (23.8) 1.000 *1
missing 1 (2.2) 1 (4.8) 0.532 *1
Maximal residual tumor diameter
Median in cm (IQR) 2.2 (1.5 – 3.9) 6.8 (2.5 – 7.6) 0.002 *2
Abbreviations
L-PCLND – laparoscopic postchemotherapy retroperitoneal lymph node dissection; O-PCLND – open postchemotherapy retroperitoneal lymph node dissection;
IQR – interquartile range; *1 – fishers exact test; *2 – Mann–Whitney U test; *3 – proportion of histologic subtype, multiple proportions in L-PCLND cohort possible.
Table 5 Relapse patients‘characteristics
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confounding factors could be differences in IGCCCG
categories and extend of follow-up, the imbalanced dis-
tribution of residual tumor diameters and histological
subtypes. Therefore, a precise statistical comparison with
reliable conclusions remains challenging. Overall this is
a descriptive series of patients undergoing PCLND for
metastatic testis cancer and some patients were mana-
ged in an inhomogeneous fashion. Some of the surgical
procedures were not performed according to established
treatment guidelines.
The results obtained for our L-PCLND patients are
comparable to those published previously [17-20]. In
2009 Calestroupat and colleagues reported their experi-
ence with 26 L-PCLND patients. Median residual tumor
diameter was 3.4 cm, while the conversion rate and theTable 4 Clavien grade III intraoperative complications
Variable L-PCLND O-PCLND
N=46 N=21
Significant lesion of V. cava 4 0
Significant lesion of Aorta 2 1
Significant lesion of iliac artery 1 1
Significant lesion of lumbal venes 1 1
Significant lesion of V. renalis 1 0
Unspecified significant bleeding 1 1
Significant lesion of the ureter (1) (1)
Significant lesion of the duodenum 0 2
Abbreviations
L-PCLND – laparoscopic postchemotherapy retroperitoneal lymph node
dissection; O-PCLND – open postchemotherapy retroperitoneal lymph node
dissection.transfusion rate were 11.5% and 3.8%, respectively. Me-
dian operative time (183 min) was relatively short with a
median hospital stay of 5 days. Grade 3/4 complications
occurred in 7.6% of cases. The authors concluded that a
high level of surgical expertise is needed to successfully
perform a L-PCLND. Although L-PCLND has been
restricted to patients with small residual tumors in the
study of Calestroupat et al., their conversion rate, trans-
fusion rate and the number of Grade3/4 complication
were higher compared to our observations [18].
In a series of 49 L-PCLND patients with residual
tumor sizes between 2-5 cm Janetschek and co-workers










Pt.#1 L-PCLND Modified Unknown, but
massive





35 month III C
Pt.#3 L-PCLND Modified New pulmonary mets
and in-field relapse
33 month II C
Pt.#4 L-PCLND Modified In-field relapse 4 month III C






Pt.#7 O-PCLND Modified Unknown, but
massive
10 month III B
Abbreviations:
L-PCLND – laparoscopic postchemotherapy retroperitoneal lymph node
dissection; O-PCLND – open postchemotherapy retroperitoneal lymph node
dissection; Mo - months.
Table 6 Outcome characteristics
Variable L-PCLND O-PCLND p
ValueN=46 N=21
Median follow up; months (IQR) 30.1 (12.1 – 47.1) 54.5 (22.0 – 87.7) 0.033 *1
Further treatment, n (%)
surveillance 33 (71.7) 12 (57.1) 0.020 *2
chemotherapy 3 (6.5) 6 (28.5)
thoracotomy 0 (0) 1 (4.8)
incomplete follow up 9 (19.6) 0 (0) 0.048 *2
Lost to follow up 1 (2.2) 2 (9.5) 0.229 *2
Tumor relapse, n (%) 4 (8.6) 3 (14.2) 0.415 *2
Estimated OS since PCLND in months
Mean± SD 83.3 ± 1.9 95.0 ± 7.4 0.447 *3
(95%CI; range) (79.6 - 87.3) (80.5 – 109.6)
Abbreviations
L-PCLND – laparoscopic postchemotherapy retroperitoneal lymph node dissection; O-PCLND – open postchemotherapy retroperitoneal lymph node dissection;
OS – overall survival; SD – standard deviation; n.s. - not statistically significant; *1 – Mann–Whitney U test *2 – fishers exact test; *3 – log-rank test.
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cation rate was low. All bleeding complications were
managed laparoscopically and no blood transfusion was
necessary. Interestingly, L-PCLND was only applied to
patients with clinical stage IIb disease, thereby partly
explaining these favourable intra- and postoperative
results [17].Figure 1 Mean estimated overall survival since PCLND. L-PCLND
– laparoscopic postchemotherapy retroperitoneal lymph node
dissection; O-PCLND – open postchemotherapy retroperitoneal
lymph node dissection.The largest L-PCLND series of 59 patients was pub-
lished by Albqami from Linz, Austria. A mean operative
time of 234 min, a conversion rate of 0%, a mean esti-
mated blood loss of 165 ml and a mean hospital stay of
3.8 days were reported. During a 5 year follow-up two
patients relapsed [19].
In 2008 Steiner et al. demonstrated the feasibility of a
bilateral L-PCLND with the preservation of sympathetic
nerves in 42 patients (stage IIB n = 19). No conversion to
O-PCLND was necessary; mean operative time was 323
min, no intraoperative complications were reported.
Antegrade ejaculation was reported for 85.7% of
patients. After a mean follow up of 17.2 months no dis-
ease recurrence was observed. Unfortunately, there were
no exact tumor diameters and locations reported in this
study [20]. Comparison to our data is therefore
challenging.
Overall, none of the above mentioned studies directly
compared L-PCLND patients with a contemporary
O-PCLND cohort.
For O-PCLND patients with initial tumor masses lar-
ger than 5 cm local relapse rates of 10% are reported in
the literature [21]. However, for extended retroperitoneal
teratoma the local disease recurrence rates following
surgery might be up to 25% [22]. In a recent series of
73 patients with small residual tumors (mean diameter
4 cm) Luz et al. reported an overall complication rate
of 27% and found viable tumor in 22% of patients [23].
In 2007, Carver et al. demonstrated that O-PCLND
patients with a residual teratoma had a 10-year recur-
rence-free survival of 80%. The residual tumor size and
the IGCCCG risk classification were independent pre-
dictors of disease recurrence [24]. These findings are in
Table 7 Subgroup analysis of residual tumors ≤7 cm
Variable L-PCLND O-PCLND p
ValueN=40 N=13
Median residual tumor diameter; cm (IQR) 2.1 (1.3 – 3.0) 6.3 (2.5 – 7.0) 0.014*2
Insertion of drainage tubes; n (%) 9 (22.5) 10 (76.9) 0.001*1
Median time of drainage tube; days (IQR) 0.0 (0.0 – 0.0) 2.5 (0.0 – 4.3) 0.001*2
Intraoperative kidney resection; n (%) 0 (0) 1 (7.6) 0.245*1
Median operative time in min (IQR) 195.0 (140 – 283) 227.5 (181 – 308) 0.292*2
Median time of hospital stay; days (IQR) 5.5 (5.0 – 7.0) 8.5 (5.5 – 13.5) 0.008*2
Abbreviations
L-PCLND – laparoscopic postchemotherapy retroperitoneal lymph node dissection; O-PCLND – open postchemotherapy retroperitoneal lymph node dissection;
IQR – interquartile range; *1 – fishers exact test; *2 – Mann–Whitney U test.
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technique, IGCCCG risk score, clinical stage or residual
tumor diameter as predictors of disease recurrence or
OS. This observation could reflect the significant differ-
ences of patient characteristics in Carvers cohort com-
pared to our study, especially with respect to the
fraction of L-PCLND patients with good prognosis and
small residual tumors.
Subramanian et al. published a detailed analysis of 98 O-
PCLND patients. Median blood loss was 1000 ml with a
consecutive transfusion rate of 42%. Median operating
time was 305 min and the median hospital stay 6 days.
Overall, intraoperative complication rate was 12%, grade
III complications were reported in 6% of cases, 1% each
for grade IV and V. Antegrade ejaculation was preserved
in 41% of patients. Unfortunately, similarly to other publi-
cations no data on tumor diameters were reported which
limits comparability to our data [13].
Reviewing O-PCLND series Heidenreich and co-work-
ers concluded that in advanced NSGCTs, a complete re-
section should be performed for all residual masses
irrespective of tumor size, location or histology, thereby
providing an excellent long-term disease-free survival of
95% [9]. For smaller tumors, a modified template resec-
tion was recommended [11].
Despite the advances in laparoscopic surgery at highly
specialized urological centers, L-PCLND still represents
an evolving technique. Patient counselling and decision
making on surgical technique used largely depends on
the surgeon’s experience, tumor characteristics and the
patient’s condition.
One of the major drawbacks in obtaining evidence on
this important issue is the fact that comparison of the
data published in the literature is challenging due to a
number of reasons: firstly different eras, in which inter-
ventions were performed [25] and secondly different
reporting systems of complications. To overcome these
issues partly, we incorporated the recently introduced
Clavien classification into our study [12]. Unfortunately,
most of the previous studies did not use this evidencebased classification, thereby precluding a sufficient
comparison.Conclusions
To our knowledge this is the largest study directly compar-
ing L-PCLND with O-PCLND patients. In concordance
with previous studies we demonstrated that L-PCLND to
represents a safe and reasonable alternative option to O-
PCLND for well selected patients with small residual
tumors. Both approaches are technically demanding and
require a high degree of surgical expertise.
Larger multicenter studies are urgently needed adjust
for confounders and better define factors qualifying
patients for L-PCLND.Methods
All patients underwent either L-PCLND (n = 46) or O-
PCLND (n = 21) at the Charité University Medicine
Berlin between October 1999 and March 2010. The Char-
ité department of urology is performing surgery in two
different locations. On one campus all residual tumor
resections were performed laparoscopically on the other
campus all by the open approach. Therefore open and
laparoscopic cases were performed concurrently and
consecutively.
Data collection was accomplished under an internal
review board-approved protocol via retrospective chart
review by means of a standardized protocol of the
GTCSG. Follow-up was obtained by phone interview
with the patients and their local urologists.
Variables of interest were preoperative data on primary
histology at the time of orchiectomy, the IGCCCG prog-
nostic risk score at initial chemotherapy as well as tumor
marker levels prior to and after chemotherapy [6]. Add-
itionally, patient characteristics and operative details
(operative technique, operative time, duration of surgical
drainage, intra- and postoperative complications accord-
ing to Clavien [26], categorized blood loss, concomitant
nephrectomy or injury of major vessels) were analyzed.
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where [18,27]. In both surgical approaches a modified
template resection was defined by the anatomic boundaries
described by Heidenreich and Lattouf et al. [11,27]. Briefly,
the right-sided modified template resection consisted of the
precaval, paracaval, retrocaval, and interaortocaval regions
as well as the area lateral to the common iliac vessels with
the crossing of the ureter as a caudal boundary. The ureter
served as the lateral and the renal vein as the cranial
boundary. Similarly the left-sided modified template resec-
tion included the preaortic area down to the inferior mes-
enteric artery, the para-aortic and retroaortic regions with
the ureteral crossing of the iliac artery as the caudal and the
ureter as the lateral boundaries of dissection. A radical tem-
plate resection was performed in case of contralateral
spread, interaortocaval tumor location, or larger residual
tumors. For a radical bilateral approach, the dissection
fields of the right- and left-modified resections were com-
bined. In defined cases, a nerve-sparing technique as
described by Steiner et al. was performed and considered a
modified approach [20]. Lumpectomy was defined as a sim-
ple resection of the residual tumor.
Blood loss category I was defined as insignificant if
<100 ml without transfusion, category II if between 100 ml
and 500 ml without transfusion and category III if blood
loss was >500 ml with or without the need for intraopera-
tive blood transfusions. The rationale for using surgical
drains in the L-PCLND cohort largely depended on the
surgeon’s intraoperative assessment of wound secretion.
Differences in categorical variables were analyzed by the
Fisher’s exact test, while continuous variables were ana-
lysed using the Mann–Whitney U test for non-normally
distributed data. Differences in mean estimated OS were
calculated by the log-rank test. Predictors of disease-free
survival and OS were analyzed in a univariate cox regres-
sion model. All tests were two-tailed, differences were con-
sidered significant with a p value <0.05. The statistical
analysis was conducted with SPSS version 18.0 (SPSS Inc.,
Chicago, IL, USA).
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